InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Lexeo Therapeutics, Inc.

LXEO Clue Score11
United States Fiscal year ends December CIK 0001907108
$3.23 +0.62% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $3.23 −67.86% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 3 Nov 2023. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2022Revenue0.7Operating income−60.5Net income−59.3EPS, diluted−36.36Fiscal year 2023Operating income−68.5Net income−66.4EPS, diluted−12.40Fiscal year 2024Operating income−105.8Net income−98.3EPS, diluted−3.09Fiscal year 2025Operating income−109.3Net income−100.0EPS, diluted−1.86
FY2022FY2023FY2024FY2025
Revenue 0.7 n/a n/a n/a
Growth
Operating income −60.5 −68.5 −105.8 −109.3
Net income −59.3 −66.4 −98.3 −100.0
Growth
EPS, diluted −36.36 −12.40 −3.09 −1.86

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2022Operating margin−9,252.1%Net margin−9,063.8%Free cash flow margin−8,445.3%Fiscal year 2023Fiscal year 2024Fiscal year 2025
FY2022FY2023FY2024FY2025
Operating margin −9,252.1% n/a n/a n/a
Net margin −9,063.8% n/a n/a n/a
Free cash flow margin −8,445.3% n/a n/a n/a

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2022Operating cash flow−54.6Capital expenditure−0.7Free cash flow−55.2Fiscal year 2023Operating cash flow−59.5Capital expenditure−0.1Free cash flow−59.6Fiscal year 2024Operating cash flow−81.2Capital expenditure−0.5Free cash flow−81.6Fiscal year 2025Operating cash flow−98.6Capital expenditure−0.4Free cash flow−99.0
FY2022FY2023FY2024FY2025
Operating cash flow −54.6 −59.5 −81.2 −98.6
Capital expenditure −0.7 −0.1 −0.5 −0.4
Free cash flow −55.2 −59.6 −81.6 −99.0
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2022Cash77.3Shareholders’ equity−113.0Fiscal year 2023Cash121.5Shareholders’ equity113.5Fiscal year 2024Cash35.0Shareholders’ equity116.8Fiscal year 2025Cash63.0Shareholders’ equity246.7
FY2022FY2023FY2024FY2025
Cash 77.3 121.5 35.0 63.0
Shareholders’ equity −113.0 113.5 116.8 246.7

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Margins
−9,252.1% n/a n/a n/a
−9,063.8% n/a n/a n/a
−9,063.8% n/a n/a n/a
−8,445.3% n/a n/a n/a
Spending
7,517.1% n/a n/a n/a
1,835.0% n/a n/a n/a
102.8% n/a n/a n/a
Returns
n/a −58.5% −84.2% −40.5%
−61.1% −47.5% −66.9% −37.2%
Balance and payout
25.7% 18.8% 20.5% 8.2%